FULL TEXT LINKS



Review

Leuk Lymphoma. 2001 Jul;42(3):275-89. doi: 10.3109/10428190109064584.

Searching for the magic bullet against cancer: the butyrate saga

V Santini ¹, A Gozzini, B Scappini, A Grossi, P Rossi Ferrini

Affiliations

PMID: 11699392 DOI: 10.3109/10428190109064584

Abstract

n-Butyric acid and its "polymorphic" derivatives have been largely but somehow "blindly" studied in oncology and in red cell diseases with consistent results through decades indicating a strong maturative effect determined by enhancement of gene transcription. Although these effects have been observed mainly in vitro, the relative absence of systemic toxicity of butyrates render these compounds appealing as specific therapeutic agents. More interestingly, their specific mechanism of action, i.e. inhibition of histone deacetylase and de-repression of transcription represents at present an unique tool for diseases such as acute leukemias which are characterised by a disregulation of corepressors and co-activators of gene transcription. More insight into specificity and modalities of action of different butyrate derivatives may be a guarantee for excellent tailored antileukemic therapy in the future.

PubMed Disclaimer

Related information

MedGen PubChem Compound PubChem Compound (MeSH Keyword) PubChem Substance

LinkOut - more resources

Full Text Sources
Taylor & Francis